Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-2750 · 1 trial · 2 indications
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by investigator will be presented.
| Arm | Type | Description |
|---|---|---|
| Part 1: Dose Comparison Cohort | EXPERIMENTAL | Participants will receive MK-2750 |
| Part 2: Signal-Finding Cohorts | EXPERIMENTAL | Participants will receive MK-2750 |
| Name | Type | Description |
|---|---|---|
| MK-2750 | BIOLOGICAL | Administered as an intravenous (IV) infusion |
| 5-HT3 serotonin receptor antagonist | DRUG | Administered as a premedication per the approved product label |
| NK-1 receptor antagonist | DRUG | Administered as a premedication per the approved product label |
| Corticosteroid | DRUG | Administered as a premedication per the approved product label |
| Steroid mouthwash (dexamethasone or equivalent) | DRUG | Administered orally per the approved product label as a rescue medication |
Inclusion Criteria: * Has histologically or cytologically confirmed advanced or metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC); advanced or metastatic NSCLC; or advanced, unresectable, or metastatic pancreatic ductal adenocarcinoma (PDAC) * Has histologically confirmed unrese...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |